Lakefront Biotherapeutics (LKFT) Cash from Financing Activities (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash from Financing Activities for 11 consecutive years, with -$597080.3 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 43.85% year-over-year to -$597080.3; the TTM figure through Mar 2026 stood at -$3.2 million (up 37.14% YoY), while the FY2025 annual figure was -$3.8 million, up 27.59% from the prior year.
• Cash from Financing Activities eased to -$597080.3 in Q1 2026 per LKFT's latest filing, from -$471437.6 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at -$28058.4 in Q1 2022 and bottomed at -$2.0 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged -$1.0 million across 5 years, with a median of -$1.1 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities slumped 626.82% — and 2025, when it surged 72.5%.
• Lakefront Biotherapeutics' Cash from Financing Activities stood at -$2.0 million in 2022, then soared by 34.55% to -$1.3 million in 2023, then tumbled by 33.76% to -$1.7 million in 2024, then soared by 72.5% to -$471437.6 in 2025, then slipped by 26.65% to -$597080.3 in 2026.
• Business Quant data shows LKFT's Cash from Financing Activities at -$597080.3 in Q1 2026, -$471437.6 in Q4 2025, and -$1.5 million in Q3 2025.